PROSCA2017

The Global Congress on Prostate Cancer brings together top experts and delegates from several disciplines, for an in-depth discussion of the different aspects of prostate cancer, with a focus on difficulties and dilemmas of clinical decision making, settled in an inspiring location.

The role of microvesicles in the hyper-coagulopathy associated with Prostate Cancer

Al Saleh

Hassan Ali

St. Joseph's Healthcare Hamilton

Hamilton

Canada

View abstract

Using Abiraterone in Metastatic Castration Resistance Prostate Cancer - Real Life Experience from two Portuguese Hospitals

Alves

Luísa

Hospital Beatriz Ângelo

Loures

Portugal

View abstract

Radiofrequency ablation of bone metastatic disease after radical prostatectomy. Preliminary results.

Andabekov

Timur

Russian Research Center for Radiology and Surgical Technologies

St.Petersburg

Russia

View abstract

Haematological toxicity from primary whole-pelvis radiotherapy in patients with high risk prostate cancer

Antunac

Katarina

University Hospital for Tumors- CHC "Sestre Milosrdnice"

Zagreb

Croatia

View abstract

Development and usability testing of the smartphone application Rotterdam Prostate Cancer Risk Calculator

Azevedo

Nuno

Centro Hospitalar do Porto

Porto

Portugal

View abstract

A prospective evaluation on the effect of inter-observer variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator

Azevedo

Nuno

Centro Hospitalar do Porto

Porto

Portugal

View abstract

The role of ERG Protein Expression and TMRPSS2-ERG Fusion in Prostatic Carcinoma Patients

Badawy

Mohamad

Theodore Bilharz Research Institute

Giza

Egypt

View abstract

LONG TERM SEXUAL MORBIDITY AFTER LOW DOSE-RATE BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER – SINGLE CENTER EXPERIENCE

Baltazar

Pedro Miguel

Centro Hospitalar Lisboa Central

Lisbon

Portugal

View abstract

Surgical approach to non-nodal oligometastasis in Prostate Cancer

Battaglia

Antonino

University Hospital

Leuven

Belgium

View abstract

Focal salvage image guided Cyberknife extreme stereotactic hypofractionated radiotherapy as management of intra-prostatic relapse after radical treatment.

Beltramo

Giancarlo

CENTRO DIAGNOSTICO ITALIANO

Milan

Italy

View abstract

Cyberknife Extreme Stereotactic Hypofractionated Radiotherapy for prostate cancer.

Beltramo

Giancarlo

CENTRO DIAGNOSTICO ITALIANO

Milan

Italy

View abstract

A prospective study of Carcinoma Prostate patients at a tertiary institute in North India with special emphasis on their bone health

Bhaskar

Ved

King George's Medical University

Lucknow

India

View abstract

Oncologic outcomes of robot assisted radical prostatectomy at single tertiary European centre with more than 10 years follow up.

Bianchi

Lorenzo

Sant'Orsola-Malpighi Hospital

Bologna

Italy

View abstract

MAGNETIC RESONANCE/ULTRASOUND-GUIDED FUSION PROSTATE BIOPSY: CANCER DETECTION RATE WITHIN CONSECUTIVE CORES TAKEN.

Bianchi

Lorenzo

Sant'Orsola-Malpighi Hospital

Bologna

Italy

View abstract

Patterns of positive surgical margins after surgery in prostate cancer patients and their association with clinical recurrence.

Bianchi

Lorenzo

University of Bologna, Sant'Orsola-Malpighi Hospital

Bologna

Italy

View abstract

Electromagnetic synchronized real-time system for MRI-TRUS fusion targeted biopsy of prostate (Toshiba Aplio 500Tm) in a heterogeneous patients cohort: results and comparison with systematic biopsy

Borghesi

Marco

Sant'Orsola-Malpighi Hospital

Bologna

Italy

View abstract

Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing the definitions of CHAARTED and LATITUDE trial

Buelens

Sarah

University hospital Ghent

Ghent

België

View abstract

Association of Rare Variants with Prostate Cancer in Korean Population

Byun

Seok-Soo

Seoul National University Bundang Hospital

Seongnam

South Korea

View abstract

Radical Prostatectomy versus External-Beam Radiotherapy in Patients With High-Risk Prostate Cancer

Chernyaev

Vitaly

Russian cancer research center

Moscow

Russia

View abstract

Evaluation of SOCS1 and its targets of tumor suppression as potential biomarkers in prostate cancer

Chevrier

Martin

CRCHUS

Sherbrooke

Canada

View abstract

SBRT and Hormone Therapy for Oligometastatic Prostate Cancer.

Conde-Moreno

Antonio Jose

Consorcio Hospitalario Provincial de Castellon

Castellon

Spain

View abstract

The role of PCA3 urine test in prostatic cancer diagnosis at repeat biopsy

Elmohamady

Basheer

Banha university hospital

Benhs

Egypt

View abstract

Improving chances of prostate cancer survival in black African men: a study of the information needs of this high-risk group in the UK and S.E. Nigeria.

Emele

Chikezie

RGU

Aberdeen

View abstract

Penile metastasis from a rare entity

Falcao

Gil

Centro Hospitalar Lisboa Central

Lisbon

Portugal

View abstract

Early experience and quality of life prostate cancer Phase I-II SBRT trials.

Ferrer

Ferran

Hospital Duran i Reynals. Catalan Institute of Oncology.

L'Hospitalet- Barcelona

Spain

View abstract

IMPACT OF EARLY SALVAGE RADIATION THERAPY IN PATIENTS WITH PSA RISE AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER

Fossati

Nicola

IRCCS Ospedale San Raffaele

Milan

Italy

View abstract

IDENTIFYING THE OPTIMAL CANDIDATE FOR SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENCE OF PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL ANALYSIS.

Fossati

Nicola

Vita-Salute University San Raffaele

Milan

Italy

View abstract

11C-CHOLINE VERSUS 68Ga-PSMA PET/CT SCAN FOR THE DETECTION OF NODAL RECURRENCE FROM PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SALVAGE LYMPH NODE DISSECTION SERIES.

Fossati

Nicola

Vita-Salute University San Raffaele

Milan

Italy

View abstract

The role of testosterone in prostate cancer growth: Is the growth response of LNCaP and PC3 cells to exogenously applied testosterone in vitro saturation dependent?

Hald

Oliver

Southampton General Hospital

Southampton

United Kingdom

View abstract

Potential role of a novel urinary biomarker-based risk score to select patients for multiparametric MRI for prostate cancer detection.

Hendriks

Rianne

Radboud university medical center

Nijmegen

The Netherlands

View abstract

Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer

Hessels

Daphne

MDxHealth B.V.

Nijmegen

The Netherlands

View abstract

Immediate treatment versus active-surveillance in very-low-risk prostate cancer: the role of hospital-related factors.

Jansen

Netherlands Comprehensive Cancer Organisation

Utrecht

The Netherlands

View abstract

The comparison of prognoses between radiotherapy and radical prostatectomy in patients with high risk localized or locally advanced prostate cancer treated with neoadjuvant hormonal therapy

Joung

Jae Young

National Cancer Center

Goyang

South Korea

View abstract

Investigation of noninvasive urine specimens with molecular profile fluctuations for a presence of high-risk Human Papilloma Viruses as an inflammatory cofactor in the complicated origin of prostate cancer

Kavrakova

Anita

Geneti Medico-Diagnostic Laboratory “Genica”

Sofia

Bulgaria

View abstract

Nadir PSA is a Strong Predictor of Treatment Outcome in Intermediate and High Risk Localized Prostate Cancer Patients Treated by Definitive External Beam Radiotherapy and Androgen Deprivation.

Khader

Jamal

King Hussein Cancer Center

Amman

Jordan

View abstract

Five key steps for a recovery of the postoperative incontinence: is there any difference between pure and robot assisted radical prostatectomy in patient with clinical T2 and T3 prostate cancer?

KIM

TAENAM

PUSAN NATIONAL UNIVERSITY HOSPITAL

PUSAN

SOUTH KOREA

View abstract

Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements

Kwon

Whi-An

Wonkwang University Sanbon Hospital

Gunpo

South Korea

View abstract

Is there an age limit for the indication of extended pelvic lymph node dissection during radical prostatectomy in patients with clinically localized prostate cancer?

Larcher

Alessandro

IRCCS Ospedale San Raffaele

Milan

Ittaly

View abstract

Favorable Gleason 3 + 4 prostate cancer shows comparable outcomes with Gleason 3 + 3 prostate cancer: implications for the expansion of selection criteria for active surveillance

Lee

Hakmin

Seoul National University Bundang Hospital

SungNam

South Korea

View abstract

Anti-tumor activities of Panax quinquefolius saponins and potential diagnostic markers in prostate cancer

Yan

Vienna General Hospital, Medical University of Vienna

Vienna

Austria

View abstract

Compliance to scheduled examinations in two Active Surveillance protocols in low-risk prostate cancer patients.

Marenghi

Cristina

Fondazione IRCCS Istituto Nazionale Tumori

Milan

Italy

View abstract

Initial clinical utility assessment of a two-gene mRNA PCR Liquid Biopsy test for Early Detection of Significant Prostate Cancer in a Dutch Peripheral Hospital

Minnee

Pieter

LangeLand Ziekenhuis

Zoetermeer

The Netherlands

View abstract

IMPACT OF EARLY BEGINNING OF ABIRATERONE ACETATE IN PATIENTS WITH METASTASTIC CASTRATON-RESISTANT PROSTATE CANCER

Muñoz-Rodriguez

Jesus

Institut Universitari Parc Tauli

Sabadell

Spain

View abstract

Comparison of multiparametric and biparametric magnetic resonance imaging cognitive targeted first round prostate biopsy for patients who had PSA level under 10 ng/ml

Nam

Jong Kil

Pusan National University Yangsan Hospital

Yangsan

South Korea

View abstract

Characteristic difference of prostate cancer between Korean patients, European Randomized Study of Screening for Prostate Cancer, Rotterdam group and Dutch clinical cohort

park

jae young

Korea University Ansan Hospital

Ansan

South Korea

View abstract

Stereotactic body radiotherapy for low- and intermediate-risk clinically localized prostate cancer

Park

Jongwook

Korea Cancer Center Hospital

Seoul

Republic of Korea

View abstract

Can length between capsule and prostate cancer burden predicts up-staging and in patients with localized prostate cancer ?

Park

Kyung Kgi

Jeju National university

Jeju

South korea

View abstract

Prostate specific antigen level after 3months of androgen deprivation therapy can predict overall survival in patients with metastatic hormone-sensitive prostate cancer.

Park

Kyung Kgi

Jeju National university

Jeju

South korea

View abstract

Initial posterior dissection during the robot assisted laparoscopic radical prostatectomy for large prostate and previous BPH surgery

Park

Sung Woo

Pusan National University Yangsan Hospital

Yangsan

South Korea

View abstract

Does T1- and Diffusion-Weighted MR Imaging give value-added than bone scintigraphy in the follow-up of vertebral metastasis of prostate cancer?

Park

Sung Woo

Pusan National University Yangsan Hospital

Yangsan

South Korea

View abstract

Head-to-head comparison of commonly used international risk calculators predicting prostate cancer

Pereira Azevedo

Nuno

Centro Hospitalar do Porto

Porto

Portugal

View abstract

Pre-operative characteristics of pT3b prostate cancer: results from the Be-RALP project

Poelaert

Filip

Ghent University Hospital

Ghent

Belgium

View abstract

MRCaP Study- Can Multiparametric MRI of the Prostate be used to identify patients in whom TRUS biopsies can be safely avoided?

Prasher

Sparsh

Barts Health NHS Trust

London

United Kingdom

View abstract

Setting up a Community Outreach Clinic to improve Prostate Cancer outcomes in an ethnically diverse community- The London Experience

Prasher

Sparsh

Newham University Hospital

London

View abstract

Wnt/β-catenin Pathway Activation in Prostate Cancer

Puig

Pere

Atryshealth

Barcelona

Spain

View abstract

Adenocarcinoma (Prostate) as a Second NonLymphoid Neoplasms in Chronic Lymphocytic Leukemia

Rashid

Munazza

National Institute of Blood Disease & Bone Marrow Transplantation Karachi, Pakistan

Karachi

Pakistan

View abstract

Gleason score upgrading in low risk prostate cancer: clinically significant findings based on an analysis of 456 radical prostatectomy cases

Raskin

Yannic

AZ Sint Blasius

Dendermonde

Belgium

View abstract

“REAL-WORLD” EXPERIENCE ON INCIDENTAL PROSTATE CANCER: RESULTS FROM A SINGLE TERTIARY CARE CENTER

Ribeiro de Oliveira

Tiago

Santa Maria Hospital

Lisbon

Portugal

View abstract

INTERNET: THE NEW PROSTATE CANCER PATIENT`S TOOL

Rodriguez Lopez

Sabela

HGUCR

Ciudad Real

Spain

View abstract

Should residents perform Laparoscopic Radical Prostatectomy? What about patients? Datebase analysis

Rodriguez Lopez

Sabela

HGUCR

Ciudad Real

Spain

View abstract

Focal irreversible electroporation as primary and salvage treatment for prostate cancer

Scheltema

Matthijs

St. Vincents Prostate Cancer Centre

Sydney

Australia

View abstract

PREOPERATIVE 11C-CHOLINE PET-CT IN INTERMEDIATE, HIGH RISK AND VERY HIGH RISK PROSTATE CANCER PATIENTS: IS THERE STILL ANY ROOM LEFT FOR IT?

Schiavina

Riccardo

Sant'Orsola-Malpighi Hospital

Bologna

Italy

View abstract

PREOPERATIVE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AND NEUROVASCULAR BUNDLE MANAGEMENT: SURGICAL PLAN CHANGE IN COURSE OF ROBOT ASSISTED RADICAL PROSTATECTOMY

Schiavina

Riccardo

Sant'Orsola-Malpighi Hospital,

Bologna

Italy

View abstract

Positive surgical margins after radical prostatectomy in obese patients: does the approach matter?

Sokolov

Egor

S.P. Botkin's State Hospital

Moscow

Russia

View abstract

One year experience with micro-CME in prostate cancer: less is more?

Stoevelaar

Herman

Ismar Healthcare

Lier

Belgium

View abstract

Diagnostic performance of MRI-transrectal ultrasound fusion prostate biopsy in detecting clinically significant prostate cancer

Tan

Teck Wei

Tan Tock Seng Hospital

Singapore

View abstract

LINAC-based VMAT Stereotactic Body Radiotherapy for low-intermediate risk Prostate Cancer: Toxicity and Quality of Life Report

Teh

Jonathan

National Cancer Centre Singapore

SIngapore

Singapore

View abstract

Superior biochemical recurrence and quality of life outcomes are achievable with robotic radical prostatectomy versus open radical prostatectomy –update of a prospective single-surgeon study of 2,206 consecutive cases

Thompson

James

St Vincent’s Prostate Cancer Centre

Sydney

Australia

View abstract

A genomic analysis of metastases-prone localized prostate cancer identifies AZIN1 as driver of metastatic progression.

Van den Broeck

Thomas

KU Leuven

Leuven

Belgium

View abstract

Parameters associated with survival in patients with metastatic castration resistant prostate cancer treated with radium-223 therapy

Van der Doelen

Maarten

Radboud University Medical Center

Nijmegen

The Netherlands

View abstract

Pelvic lymph node dissection in prostate cancer staging: evaluation of morbidity and therapeutic effect

Van Huele

Andries

Ghent University Hospital

Ghent

Belgium

View abstract

High Dose Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Intermediate-Risk Prostate Cancer: preliminary results of toxicity and quality of life

Viveiros

Cláudia

Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE

Lisbon

Portugal

View abstract

177 Lu-PSMA-617 radioligand therapy for biohemically recurrent prostate cancer

von Eyben

Finn

Center of Tobacco Control Research

Odense

Denmark

View abstract

177 Lu-prostate specific membrane antigen-617 radioligand therapy for patients with lymph node metastases of prostate cancer

von Eyben

Finn

Center of Tobacco Control Research

Odense

Denmark

View abstract

Developing and implementing a community-based prostate cancer awareness and early detection campaign for hard to reach men

Wheelwright

Roger

Croydon University Hospital

Croydon

United Kingdom

View abstract

Community based prostate cancer nurse specialist to provided integrated and seamless care between secondary and primary care

Wheelwright

Roger

Croydon University Hospital

Croydon

View abstract

Potential biomarkers for prostate cancer screening

Yoon

JinSun

Bio-Medical Science Co.Ltd

Seoul

Korea

View abstract

Hormone therapy and the severity of depressive symptoms in patients undergoing treatment for prostate cancer

Yoon

Sang Jin

Gachon University Gil Medical Center

Incheon

Republic of Korea

View abstract

RESULTS OF A STANDARDIZED PHYSICAL TRAINING PROGRAM ON ADVERSE EFFECTS OF ADT IN MEN WITH PROSTATE CANCER

Zabegalina

Natalia

University Hospital Antwerp

Antwerp

Belgium

View abstract

Effect of opportunistic PSA screening for prostate cancer in a high mortality rate country

Zarkovski

Mihhail

Tartu University Hospital

Tartu

Estonia

View abstract

Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment

Ziouziou

Hajer

institue paolie calmette marseille

Marseille/Bizerte

France/Tunisie

View abstract